Foto: Jim Vondruska/Reuters/Ritzau Scanpix

A weight loss startup touting mindfulness, Noom is now prescribing drugs

The startup used to recommend a psychological path to weight loss but will now use drugs to get there.

For subscribers

US officials probe a new layer in opaque drug pricing, supply system

US authorities are looking into new groups that were formed to negotiate drug discounts but may actually be further obscuring how much the medicines cost.

For subscribers

Pharma & biotech

New production plant sparks hopes of profit at antibiotics maker

After five years, Xellia Pharmaceuticals is ready to service the US market with a new US production line.

For subscribers

Medtech

Ambu blames hospital staff shortage for European setback

The medtech company’s negative growth in Europe is being worked on, emphasizes the company’s CEO, Britt Meelby Jensen.

For subscribers

Did you read?

A weight loss startup touting mindfulness, Noom is now prescribing drugs

The startup used to recommend a psychological path to weight loss but will now use drugs to get there.

For subscribers

Pharma & biotech

Heartseed raises USD 14m for stem-cell therapy development

With proceeds from a Series D round, a phase I/II trial can be completed with a stem-cell therapy candidate against heart failure to which Novo Nordisk retains global rights outside Japan.

For subscribers

Demant is fighting tooth and nail to get rid of its surgical division

Hearing health

Demant proposes partial Oticon Medical divestment to ease competition concerns

An analyst at investment bank ABG assesses that Demant has a tough nut to crack in closing the Oticon Medical divestment as originally envisioned.

For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Jobs

See all jobs

Regulation

CHMP recommends two drugs in May

One drug to diagnose prostate cancer and one to treat epileptic seizures are all the EMA’s expert committee has nominated for full approval during its meeting this month.

For subscribers

Did you read?

Demant proposes partial Oticon Medical divestment to ease competition concerns

An analyst at investment bank ABG assesses that Demant has a tough nut to crack in closing the Oticon Medical divestment as originally envisioned.

For subscribers

Other

Top news from MedWatch this week

News about Novo Nordisk, Genmab, Demant, Cochlear, GN, Argenx, Beta Bionics, Catalent, and new EU drug approvals.

According to GN, there has only been few cases of infection in the company's market organization | Foto: Pr

Hearing health

GN considers Covid-19 situation far less critical than six months ago

Hearing health group GN remains unaffected by the increase in Covid-19 cases that is being detected in China where the Danish company has production facilities.

For subscribers

Pharma & biotech

Novo Nordisk wins EU recommendation for label extension of long-acting growth hormone

The EMA’s expert committee has taken a positive stance on the Danish drugmaker’s treatment for children over three years with growth hormone deficiencies.

For subscribers

Pharma & biotech

Novo Nordisk's semaglutide shows potential against addiction

An analyst says it’s too early to say whether Novo Nordisk’s ”golden molecule” has commercial potential to treat addiction, however.

For subscribers

Did you read?

Heartseed raises USD 14m for stem-cell therapy development

With proceeds from a Series D round, a phase I/II trial can be completed with a stem-cell therapy candidate against heart failure to which Novo Nordisk retains global rights outside Japan.

For subscribers

Article series: Pharma & biotech

Eli Lilly drug slows Alzheimer’s disease, study finds

For subscribers

Read the article here

Spanish dermatology group Almirall and the research institution Center for Genomic Regulation have agreed on a new partnership. | Foto: Almirall / Pr

Pharma & biotech

Almirall to collaborate with Spanish research center on skin cancer treatment

In a new strategic collaboration, Spanish dermatology company Almirall and the Center for Genomic Regulation will work on identifying new treatments for non-melanoma skin cancer.

For subscribers

Researchers fear losing support for their research if making any critical statement about the Novo Nordisk Foundation | Foto: Novo Nordisk Fonden / Pr

Other

Researchers fear falling from favor with Novo Nordisk Foundation

A string of researchers fear losing support for their work if they publicly criticize the Novo Nordisk Foundation, writes Danish news outlet.

For subscribers

Hearing health

Cochlear sees no other suitors for Demant's implants business

The Australian would-be buyer has serious questions about ”whether any other company has the ability and the willingness” to shoulder the responsibility of Oticon Medical.

For subscribers

Novo Nordisk doesn't expect home run with new gene-editing therapy collaboration

The agreement between Novo Nordisk and US-based Life Edit Therapeutics is at a stage where Novo can’t say what results will be.

For subscribers

Hearing health

GN completes DKK 2.7bn capital raise

A directed share issue saw 17.3 million GN shares sold, of which 13.7 million were new issues.

For subscribers

Gitte Aabo, CEO of GN | Foto: Gn Hearing / Pr

Hearing health

GN CEO on new capital plan: "You should always have a plan B"

The hearing firm listened to shareholders and pivoted to its backup solution to debt problems.

For subscribers

Hearing health

New GN capital plan removes some stock risks, assesses bank

The focus will now return to the hearing company’s underlying business, says Jyske Bank in an analysis.

For subscribers

Hearing health

Analyst: Share sale doesn't solve all of GN's debt problems

GN’s capital raise could be described as a partial solution that does not resolve hearing company’s debt issues entirely, according to ABG Sundal Collier analyst.

For subscribers